scispace - formally typeset
Journal ArticleDOI

Renal and Hepatic Transporter Expression in Type 2 Diabetic Rats

TLDR
Research in type 2 diabetic rats investigated alterations in the renal and hepatic expression of organic anion and cation transporters, multidrug resistance-associated proteins (Mrps), breast cancer resistance protein (Bcrp), P-glycoprotein (Pgp), and hepatatic Na(+)-taurocholate cotransporting polypeptide (Ntcp) in type 1 diabetic rats to investigate changes in chemical disposition and drug pharmacokinetics.
Abstract
Membrane transporters are critical for the uptake as well as elimination of chemicals and by-products of metabolism from the liver and kidneys. Since these proteins are important determinants of chemical disposition, changes in their expression in different disease states can modulate drug pharmacokinetics. The present study investigated alterations in the renal and hepatic expression of organic anion and cation transporters (Oats/Octs), multidrug resistance-associated proteins (Mrps), breast cancer resistance protein (Bcrp), P-glycoprotein (Pgp), and hepatic Na+-taurocholate cotransporting polypeptide (Ntcp) in type 2 diabetic rats. For this purpose, type 2 diabetes was induced by feeding male Sprague- Dawley rats a high fat diet followed by a single dose of streptozotocin (45 mg/kg, i.p., in 0.01 M citrate buffer pH 4.3) on day 14. Controls received normal diet and vehicle. Kidney and liver samples were collected on day 24 for generation of crude plasma membrane fractions and Western blot analysis of Oat, Oct, Mrp, Bcrp, Pgp, and Ntcp proteins. With regards to renal uptake transporters, type 2 diabetes increased levels of Oat2 (2.3-fold) and decreased levels of Oct2 to 50% of control kidneys. Conversely, efflux transporters Mrp2, Mrp4, and Bcrp were increased 5.4-fold, 2-fold, and 1.6-fold, respectively in type 2 diabetic kidneys with no change in levels of Mrp1, Mrp5, or Pgp. Studies of hepatic transporters in type 2 diabetic rats reveal that the protein level of Mrp5 was reduced to 4% of control livers with no change in levels of Bcrp, Mrp1, Mrp2, Mrp4, Ntcp, or Pgp. The changes reported in this study may have implications in type 2 diabetic patients.

read more

Citations
More filters
Journal ArticleDOI

Drug transport by Organic Anion Transporters (OATs).

TL;DR: Based on IC₅₀ values reported in the literature, OAT1 and OAT3 show comparable affinities for diuretics, cephalosporins, and nonsteroidal anti-inflammatory drugs whereas OAT2 has a lower affinity to most of these compounds.
Book ChapterDOI

In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy.

TL;DR: For all transporters, information on cloning, tissue distribution, factors influencing OAT abundance, interaction with endogenous compounds and different drug classes, drug/drug interactions and, if known, single nucleotide polymorphisms is provided.
Journal ArticleDOI

Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus

TL;DR: For drugs mainly metabolized via hepatic CYP isozymes, the changes in the total area under the plasma concentration–time curve from time zero to time infinity (AUC) of metabolites, AUCmetabolite/AUCparent drug ratios, or the time‐averaged nonrenal and total body clearances of parent drugs as reported in the literature have been compared.
Journal ArticleDOI

PEGylated graphene oxide-mediated quercetin-modified collagen hybrid scaffold for enhancement of MSCs differentiation potential and diabetic wound healing

TL;DR: This study provides new prospects for the design of innovative GO-PEG-based collagen hybrid scaffolds for application in efficient therapeutic drug delivery, stem cell-based therapies, tissue engineering and regenerative medicine.
Journal ArticleDOI

Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state

TL;DR: This review provides updated information on the influence of physicochemical properties and the relevance of transporters in renal clearance and the associated drug interactions as well as tools to predict the renal clearance at the discovery stage along with the potential alterations in drug disposition in the renal disease state.
Related Papers (5)